Insulin resistance syndrome and fibrinolytic activity: The Northern Sweden MONICA Study

International Journal of Epidemiology

Volumn 25, Issue 2, 1996, Pages 291-299

  Lindahl, Bernt ^a   Asplund, Kjell ^b   Eliasson, Mats ^c   Evrin, Per Eric ^d  

^a UMEÅ UNIVERSITY   (Sweden)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^c Lulea Hospital   (Sweden)

^d Boden Hospital   (Sweden)

Author keywords

Epidemiology; Fibrinogen; Fibrinolysis; Hyperinsulinism; Insulin resistance; PAI 1 activity; tPA activity; Triglycerides

Indexed keywords

GLUCOSE; INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; FEMALE; FIBRINOLYSIS; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; SWEDEN; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; CARDIOVASCULAR DISEASES; FEMALE; FIBRINOLYSIS; HUMANS; INSULIN RESISTANCE; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; POPULATION SURVEILLANCE; RISK FACTORS; SWEDEN; SYNDROME; TISSUE PLASMINOGEN ACTIVATOR; TRIGLYCERIDES;

EID: 0030009242     PISSN: 03005771     EISSN: None     Source Type: Journal    
DOI: 10.1093/ije/25.2.291     Document Type: Article

References (48)

1. Nordoy A. Haemostatic factors in coronary heart disease. J Intern Med 1993; 233: 377-83.
2. DeWood M A, Spores J, Notske R et al. Prevalence of total coronary occlusion during the early hours of transmural infarction. N Engl J Med 1980; 303: 897-902.
3. Ernst E, Resch K L. Fibrinogen as a cardiovascular risk factor: A meta-analysis and review of the literature. Ann Intern Med 1993; 118: 956-63.
4. Folsom A R, Wu K K, Davis C E, Conlan M G, Sorhe P D, Szklo M. Population correlates of plasma fibrinogen and factor VII. putative cardiovascular risk factors. Atherosclerosis 1991; 91: 191-205
5. Ehasson M, Evrin P E, Lundblad D, Asplund K, Rånby M. Influence of gender, age and sampling time on plasma fibrinolytic variables and fibrinogen - a population study. Fibrinolysis 1993; 7: 316-23.
6. Wimau B, Hamsten A. Impaired fibrinolysis and risk of thromboembolism. Prog Cardiovasc Dis 1991; 34: 179-92.
7. Dawson S, Henney A. The status of PAI-1 as a risk factor for arterial and thrombotic disease: A review. Atherosclerosis 1992, 95: 105-17.
8. Juhan-Vague I, Thompson S G, Jespersen J Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. Arterioscler Thromb 1993; 13: 1865-73.
9. Hamsten A, Walldius G, Szamosi A et al. Plasminogen activator inhibitor in plasma. Risk factor for recurrent myocardial infarction. Lancer 1987; ii: 3-9.
10. Reaven G M. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
11. Modan M, Halkin H, Almog S et al. Hyperinsulinemia. A link between hypertension, obesity and glucose intolerance. J Clin Invest 1985; 75: 809-17.
12. DeFronzo R A, Ferrannini M D. Insulin resistance. A multifaceted syndrome responsible for NIDDM. obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-94.
13. Ferrannini E, Natali A. Essential hypertension, metabolic disorders, and insulin resistance. Am Heart J 1991; 121: 1274-82.
14. Vague P, Raccah D. The syndrome of insulin resistance. Horm Res 1992; 38: 28-32.
15. Lindahl B, Asplund K, Hallmans G. High serum insulin, insulin resistance and their associations with cardiovascular risk factors. The Northern Sweden MONICA population study. J Intern Med 1993, 234: 263-70.
16. Eschwege E, Richard J L, Thibult N et al. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels. The Paris Prospective Study, ten years later. Horm Metab Res 1985; 15: 41-46.
17. Pyorälä K, Savolainen E, Kaukola S, Haapakoski J Plasma insulin as coronary heart disease risk factor: relationships to other risk factors and predictive value during 91/2-year follow-up of the Helsinki Policemen Study population. Acta Med Scand 1985, 701: 38-52.
18. Laakso M, Sarlund H, Salonen R et al. Asymptomatic atherosclerosis and insulin resistance. Arterioscler Thromb 1991; 11: 1068-76.
19. Eliasson M, Asplund K, Evrin P E, Lindahl B, Lundblad D. Hyperinsulinemia predicts low tissue plasminogen activator activity in a healthy population. The Northern Sweden MONICA Study. Metabolism 1994; 43: 1579-586.
20. Potter van Loon B J, Kluft C, Radder J K, Blankenstein M A, Meinders A E. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 1993; 42: 945-49.
21. Vague P, Raccah D, Juhan-Vague I Hemobiology, vascular disease and diabetes with special reference to impaired fibrinolysis. Metabolism 1992; 41: 2-6
22. Vague P, Juhan-Vague I. Aillaud M F et al. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects Metabolism 1986; 35: 250-53.
23. Scelles V, Raccah D, Alessi M C, Vialle J M, Juhan-Vague I, Vague P. Plasminogen activator inhibitor 1 and insulin levels in various insulin resistance states. Diabetes Metab 1992; 18: 38-42.
24. Eliasson M, Evrin P E, Lundblad D. Fibrinogen and fibrinolytic variables in relation to anthropometry, lipids and blood pressure. The Northern Sweden MONICA study, J Clin Epidemiol 1994; 47: 513-24.
25. Huhtasaari F, Asplund K, Wester P O. Cardiovascular risk factors in the Northern Sweden MONICA Study. Acta Med Scand 1988; 224: 99-108.
26. WHO Expert Committee on Diabetes Mellitus. Technical Report Series 727, Geneva: WHO, 1985
27. Wright B M, Dore C F. A random-zero sphygmomanometer. Lancet 1970; i: 337-38.
28. Rånby M, Sundell B, Nilsson T K. Blood collection in strong acidic citrate anticoagulant used in a study of dietary influence on basal tPA activity. Thromb Haemost 1989; 62: 917-22.
29. Bergman R N, Finegood D T, Ader M. Assessment of insulin sensitivity in vivo. Endocr Rev 1985; 6: 45-68.
30. Matthews D R, Hosker J P, Rudenski A S, Naylor B A, Treacher D F, Turner R C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-19.
31. Cederholm J, Wibell L. Insulin release and peripheral sensitivity at the oral glucose tolerance test. Diabetes Res Clin Pract 1990; 10: 167-75
32. SAS Institute Inc. SAS/STAT User's Guide, Release 6.04 Edn. Cary, North Carolina: SAS Institute Inc., 1988.
33. Mykkänen L, Rönnemaa T, Marniemi J, Haffner S M, Bergman R, Laakso M. Insulin sensitivity is not an independent determinant of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1994, 14: 1264-71.
34. Vague P, Juhan-Vague I, Alessi M C, Badier C, Valadier J. Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non-diabetic obese subjects. Thromb Haemost 1987; 57: 326-28
35. Nilsson T K, Sundell B I, Hellsten G, Hallmans G. Reduced plasminogen activator inhibitor activity in high consumers of fruits, vegetables and root vegetables. J Intern Med 1990; 227: 267-71.
36. Folsom A R, Qamhieh H T, Wing R R et al. Impact of weight loss on plasminogen activator inhibitor (PAI-1), Factor VII, and other hemostatic factors in moderately overweight adults. Anerioscler Thromb 1993; 13: 162-69.
37. Laakso M. How good a marker is insulin level for insulin resistance? Am J Epidemiol 1993; 137: 959-65.
38. Phillips D I W, Clark P M, Hales C N, Osmond C. Understanding oral glucose tolerance: Comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabetic Med 1994; 11: 286-92.
39. Olefsky J M, Farquhar J W, Reaven G M. Reappraisal of the role of insulin in hypertriglyceridemia. Am J Med 1974; 57: 551-60
40. Salomaa V V, Tuomilehto J, Jauhiainen M et al. Hypertriglyceridemia in different degrees of glucose intolerance in a Finnish population-based study. Diabetes Care 1992; 15: 657-65.
41. Gough S C L, Rice P J S, McCormack L, Chapman C, Grant P J. The relationship between plasminogen activator inhibitor-1 and insulin resistance in newly diagnosed type 2 diabetes mellitus. Diabetic Med 1993, 10: 638-42.
42. Steiner G Altering triglyceride concentrations changes insulinglucose relationships in hypertriglyceridemic patients. Double- blind study with gemfibrozil with implications for atherosclerosis. Diabetes Care 1991; 14: 1077-81.
43. Juhan-Vague I, Alessi M C, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991; 34: 457-62.
44. Asplund-Carlson A, Hamsten A, Wiman B, Carlson L A Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men. Diabetologia 1993; 36: 817-25.
45. Sliko-Rahm A, Wiman B, Hamsten A, Nilsson J. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 1990; 10: 1067-73.
46. Grant P J, Kruithof E K O, Felley C P, Felber J P, Bachmann F. Short-term infusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor-1 concentrations in man. Clin Sci 1990; 79: 513-16.
47. Schneider D J, Nordt T K, Sobel B E. Stimulation by proinsulin of expression of plasminogen activator inhibitor type-1 in endothelial cells. Diabetes 1992; 41: 890-95.
48. Barker D J P, Hales C N, Fall C H D, Osmond C, Phipps K, Clark P M S. Type 2 (non-insuhn-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia 1993; 36: 62-67.